* First Wave BioPharma Inc reported a quarterly adjusted loss of $5.35 per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of $-189.40. The mean expectation of two analysts for the quarter was for a loss of $4.03 per share. Wall Street expected results to range from $-4.93 to $-3.14 per share.
* Reported revenue was zero; analysts expected zero.
* First Wave BioPharma Inc's reported EPS for the quarter was a loss of $5.35.
* The company reported a quarterly loss of $4.18 million.
* First Wave BioPharma Inc shares had held steady so far this quarter and gained 4.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 8.3% in the last three months.
* In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is "hold."
Wall Street's median 12-month price target for First Wave BioPharma Inc is $36.00 This summary was machine generated from LSEG data April 1 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -4.03 -5.35 Missed
Sep. 30 2023 -12.30 -9.20 Beat
Jun. 30 2023 -20.80 -37.80 Missed
Mar. 31 2023 -42.60 -36.40 Beat
Comments